MTARC1 A165T — The Liver-Protective Variant That Turns Down Hepatic Fat Storage
Your liver is the body's central hub for fat metabolism, processing everything from
dietary fats to the lipids your own cells produce. The MTARC1 gene | mitochondrial
amidoxime reducing component 1, formerly known as MARC1
encodes an enzyme anchored in the outer mitochondrial membrane that plays a surprising
role in regulating hepatic lipid accumulation. The rs2642438 variant — specifically the
A allele encoding the p.Ala165Thr amino acid change — is one of the clearest examples
of a common protective variant in liver disease genetics. About 9% of people of European
descent carry two protective copies, and 42% carry one. The effect scales with allele
dose: more A alleles, less liver fat, lower risk of disease progression.
The Mechanism
At position 165 in the MTARC1 protein, the common G allele encodes an alanine residue
that is critical for protein stability. When the A allele substitutes threonine at this
position, the protein becomes dramatically less stable. Laboratory studies show the
half-life of MTARC1 drops from 11.5 hours to just 3.5 hours in liver cells | measured
by cycloheximide chase assays in HepG2 and Huh-7 hepatocyte lines.
The destabilized protein is rapidly degraded by the proteasome, reducing total MTARC1
levels in the cell by approximately 50%.
This matters because MTARC1 normally promotes fat accumulation in hepatocytes. When
MTARC1 is reduced, the beta-oxidation rate doubles in primary human hepatocytes |
measured by radiolabeled palmitate oxidation assays —
meaning the liver burns more fat rather than storing it. Protective allele carriers
also show elevated plasma 3-hydroxybutyrate | the ketone body produced as a byproduct
of fatty acid beta-oxidation, confirming
this accelerated fat oxidation in living humans from the UK Biobank. Additional
mechanisms include increased hepatic phosphatidylcholine levels (particularly
polyunsaturated species) and suppression of ferroptosis, an iron-dependent cell
death pathway implicated in NASH progression.
The Evidence
The evidence for rs2642438 is unusually strong for a common metabolic variant. The
seminal genome-first study analyzed over 460,000 participants in the UK Biobank plus
15,000 in the Penn Medicine BioBank | with median 10-12 year follow-up and full
mortality ascertainment. Each A allele
reduced NAFLD risk by approximately 15%. Homozygous AA individuals showed a hazard
ratio of 0.61 (95% CI: 0.46–0.81) for liver-related death — a 39% reduction. In
people with diabetes (who face amplified liver disease risk), the protection was
even greater: HR 0.44 [0.22–0.86].
The protective effect holds across ancestries. While the A allele is rarer in
people of African ancestry (~7% vs ~29% in Europeans), African American carriers
in the Penn Medicine BioBank showed the same distinctive lipid phenotype and
protective direction of effect. The A allele is also rarer in East Asian populations
(~8%), making this predominantly a European-frequency protective variant.
A Mendelian randomisation analysis using multi-trait colocalisation | treating the
genetic variant as a natural experiment to infer causality
confirmed that MTARC1 expression is causally related to liver fat, liver enzymes,
and plasma lipids — ruling out confounding as an explanation for the associations.
A targeted MTARC1 knockdown using GalNAc-siRNA in a diet-induced NASH mouse model
reduced liver triglycerides, total cholesterol, and fibrosis gene expression,
validating MTARC1 inhibition as a therapeutic strategy.
Importantly, the protective lipid profile of A allele carriers — lower LDL, lower
ApoB, lower total cholesterol, higher triglycerides — does not translate into
cardiovascular harm. Cardiac MRI and carotid ultrasound in the UK Biobank found
no structural cardiac differences, and cardiovascular mortality was not increased.
Practical Actions
For people carrying the protective A allele (either one or two copies): the biology
is working in your favor for liver health. Your hepatocytes are naturally more
efficient at burning fat rather than storing it, and your baseline risk of NAFLD
and liver fibrosis is meaningfully lower than the population average. This advantage
is most clinically relevant if you carry risk variants at other liver-disease loci
such as PNPLA3 (rs738409) or TM6SF2 (rs58542926), where MTARC1's protection
can partially offset the harm.
For people carrying two G alleles (the most common genotype): you have typical
MTARC1 protein stability and no extra protection against hepatic fat accumulation.
Diet quality, alcohol avoidance, and metabolic health management are the main
levers available. Choline-rich foods (eggs, liver, fish) support phosphatidylcholine
synthesis, which is specifically depleted in NAFLD and lower in GG individuals
compared to A allele carriers. Dietary saturated fat restriction is particularly
important, as GG individuals process hepatic fat less efficiently.
Interactions
The MTARC1 protective effect is strongest in the context of other liver disease
risk factors. In UK Biobank participants who also carried the PNPLA3 rs738409 G
allele (which increases NASH risk), MTARC1 AA homozygotes showed a hazard ratio
of 0.43 [0.27–0.71] for liver-related mortality — indicating the two genes interact
epistatically. The MTARC1 A allele partially offsets PNPLA3-driven fibrosis risk.
A similar protective interaction has been documented with HSD17B13 (rs72613567),
another protective liver variant; individuals carrying protective alleles at multiple
loci have additive reductions in fibrosis risk.
All Genotypes
Typical MTARC1 activity — no extra protection against liver fat accumulation
You carry two copies of the common G allele, which produces fully stable MTARC1 protein. This is the most common genotype in European populations (~49%) and represents the baseline — no extra genetic protection against hepatic fat accumulation. Your liver's fat-burning efficiency is standard, meaning diet, alcohol intake, and metabolic health are your primary determinants of liver disease risk.
One protective copy — meaningfully lower liver fat risk than average
You carry one protective A allele and one common G allele. This heterozygous genotype — present in about 42% of Europeans — confers a meaningful dose of liver protection. Each A allele reduces NAFLD risk by approximately 15%, and your MTARC1 protein levels are roughly 25% lower than GG individuals, giving your liver an intermediate fat-burning advantage. Your liver-related mortality risk is modestly reduced compared to GG homozygotes (HR ~0.85).
Two protective copies — substantially lower liver fat, NAFLD, and fibrosis risk
You carry two copies of the protective A allele at rs2642438, the rarest and most protective genotype (~9% of Europeans). Your MTARC1 protein levels are approximately 50% lower than in GG individuals because the Thr165 substitution makes the protein degrade rapidly. This dramatically boosts your hepatocytes' fat-burning rate, reduces hepatic fat storage, and significantly lowers your risk of NAFLD, NASH, and liver fibrosis.